BLRX chart is looking pretty prone for a breakout. BLRX has been undergoing consolidation and it appears to be ready to go higher Technical Analysis: BB and Keltner Channel Squeeze Price and Volume Trend during consolidation Positive Volume Index Regression Slope Rate of Change Money Flow Small Wave Count Overall Chart (Weekly) Overall...
BLRX BL-8040 Overview BL-8040 is a novel, short peptide that functions as a high-affinity antagonist for CXCR4, which BioLineRx is developing for the treatment of solid tumors, acute myeloid leukemia, or AML, and stem-cell mobilization for bone-marrow transplantation. Solid Tumors: In January 2016, BioLineRx entered into a collaboration with MSD, known as ...
A long trade can be initiated around 675 levels, if Aurobindo Pharma sustains above it's resistance zone above 650, with targets close to 800 and a stop loss around 615. The Risk to reward is high, with the trade having high probabilities of success, if 675 is tested and our entry price is hit.
ENDP Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced...
I will not go into details on this one. Bottom line is, I am impressed with Otsuka's vision and its recent developments - and many other things which I will not explain here. I will be entering a long position soon, watching the action at these levels. This is will be one of the stocks I would recommend to add to your stocks portfolio. -Keep it Real-
I need to do more research before offering a formal opinion, but i bought for TA reasons at 0035 so i wanted to share the chart now that it's making a real move and the cancer drug they make is showing promise. Looks like we could see .01 before a pullback, but the volume is insane so who knows where it ends up.
Another pharma stock here for those interested. These are often hit or miss, but NEOS has a solid floor and a lot of room to move if it gets going. Worth watching and maybe taking a shot with a small bet (not financial advice -- do we really have to say that when were obviously just finger-painting projections?) haha, GLTA!
Biogen's (344.10 at close at the date of this writing) and Eisai's recent success with BAN24O1, an experimental medication for Alzheimer's which is currently in mid-stage clinical trials, in addition to a recent price target raise by Citi, and overall bullish analyst sentiment led to a rally between July 6-9, 2018. Although the clinical trial's success was...
ATNX may be a tad over extended for now and will likely retrace to it's 18.50 or high 17's support area. May look for a buy in here. ANTX recently named Timothy Cook as senior vice president of global commercial oncology. This is recent add to an all star team in the oncology pharma space. I see a bright future for this asset. ***Any information represented...
FOR EDUCATION / PAPER TRADING PURPOSE. Buy as per Left Shoulder support and Fibonacci confluence. With STOP below the Fib 0.
I expect big pharma to love the opportunity to get the chance to trial drugs on humans using informed consent as djt just signed the 'right to try act'. Should be good for them and the terminally ill tbh GL HF xoxo snoop
Disclaimer, TEVA is in a very bad financial position, with dwindling cashflows and large debt. Buffet has always been the king of "value investing", hence why a position in Teva isn't surprising from him - it's most likely that he sees the company as severely undervalued and is entering into stages of repair. Buffet's new position in Teva was widely publicised...
Last post: April 28th. See chart . Review: Price had broken out of consolidation and was trending well following this. Update: Price is fast approaching £1.00 where it may find resistance. Conclusion: Once price breaks through £1.00 we can look for long opportunities. Any comments or questions, do not hesitate to leave them below. Hit agree if you share our...
SGYP seems to be setting up for a big big move. The Squeeze Momentum Indicator has been forming a triangle which is now about to close and the crosses in the indicator have been black for some time meaning that a release of the squeeze should be about to manifest. My guess is that spike will be to the upside, and it could go as high as 3.60$ (90%+ appreciation),...
MACD crossing coming soon. Pharma stocks usually take off quick.
Another pharma stock that just crossed on MACD. Looking for a nice run with this one.